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Resveratrol is a polyphenolic compound produced in 
some plants in response to stress, such as injury or 
infection [1] and is present most notably in red wine.  A 
number of seemingly unrelated health benefits have 
been attributed to resveratrol, including protection 
against type 2 diabetes, cancer, heart disease, 
inflammation and neurodegenerative diseases.   
However, what these diseases have in common is their 
association with aging.  Therefore, when resveratrol 
was reported to be a Sirt1 activating compound (STAC) 
[2], it captured the imagination of the field of aging.  
  
The controversy regarding the mechanism of action for 
resveratrol arose when a series of papers demonstrated 
that it activated Sirt1 only if the substrate is attached to 
a fluorophore or a bulky amino acid [3-7].  However, 
resveratrol activated Sirt1 in vivo.  One potential 
explanation is that the peptide modifications somehow 
mimicked the structure of the substrate in vivo.   
Another potential explanation is that resveratrol 
indirectly activates Sirt1 by targeting another protein.  It 
has been known for some time that resveratrol indirectly 
activates AMP-activated protein kinase (AMPK) [8], a 
well-known regulator of energy metabolism that is also 
activated by calorie restriction (CR) [9,10]. We and 
others showed that resveratrol-mediated activation of 
AMPK increases NAD
+, the cofactor for Sirt1, as well 
as Sirt1 activity [11,12].  Consistent with the central 
role of AMPK in resveratrol action, the metabolic 
effects of resveratrol disappeared in AMPK knock-out 
mice [12].  These findings, in conjunction with the 
observation that resveratrol-mediated activation of 
AMPK does not require Sirt1 [12], indicated that 
AMPK is upstream of Sirt1 and that the direct target of 
resveratrol is upstream of AMPK. 
 
One of the proposed mechanisms by which resveratrol 
activates AMPK is inhibition of ATP production.   
However, except at high concentrations of resveratrol 
(>100  μM), ATP levels do not decrease in the time 
frame of AMPK activation [13,14], suggesting another 
mechanism of action. In response to conditions that 
decrease serum glucose such as CR, glucagon and 
catecholamines are released.  These hormones stimulate 
adenylate cyclases (AC), resulting in increased cAMP 
production.  To explain the CR-mimetic effects of res- 
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veratrol, we measured cAMP levels in resveratrol-treated 
myotubes and discovered that resveratrol, at low 
micromolar concentrations (<10 μM), increased cAMP 
levels [15].  After ruling out the possibility that 
resveratrol activates AC, we discovered that resveratrol 
increased cAMP levels by competitively inhibiting a 
number of cAMP phosphodiesterases (PDEs), which 
degrade cAMP. We tested PDEs 1-5 and found that 
resveratrol inhibits PDEs 1, 3 and 4. cAMP, in turn, 
activates AMPK by increasing the activities of the 
AMPK kinases CamKKβ and, in some conditions LKB1, 
via cAMP effector proteins Epac1 (cAMP guanine-
nucleotide exchange factor) or PKA, respectively.  In 
addition, PKA-mediated phosphory-lation of S434 has 
been shown to activate Sirt1 [16].  Thus, increasing 
cAMP levels can activate Sirt1 by a number of pathways. 
 
Since there are 11 PDE family members, each with 
different properties and tissue expression patterns, it 
would be impossible to mimic all of resveratrol effects 
with just one PDE inhibitor.  However, PDE4 is the 
predominant PDE activity in skeletal muscle, the tissue 
where the metabolic effects of resveratrol are best 
elucidated.  We found that the PDE4 inhibitor rolipram 
was sufficient to activate AMPK and Sirt1 in myotubes 
and to reproduce, at least qualitatively, the metabolic 
effects of resveratrol in skeletal muscle, as well as to 
improve glucose tolerance in obese mice [15].  It is 
unlikely that inhibition of PDE4 alone or of cAMP 
PDEs together explains all of the effects seen with 
resveratrol.  The target(s) of resveratrol will most likely 
depend on the tissue, the effects of interest and the 
organism being studied. 
 
One area where we lack understanding is the 
intracellular concentration of resveratrol.  The serum 
level of unmodified resveratrol is low (submicromolar 
to low micromolar) because most resveratrol in serum is 
present in the conjugated form (e.g. glucuronide).   
However, tissues such as skeletal muscle have 
glucuronidases, which can potentially removed the 
conjugate and increase the intracellular levels of 
unmodified resveratrol far above those in the serum.  
 
The mechanism by which novel chemical entity (NCE) 
STACs activate Sirt1 in vivo is also under question 
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against native substrates in vitro, suggesting that they 
may activate Sirt1 indirectly in vivo [5,7].   
Interestingly, analyses of off-target activities of NCE 
STACs SRT1720, 2183 and 1460 showed that they are 
stronger PDE inhibitors than resveratrol [7], raising the 
possibility that they too may be activating Sirt1 in vivo 
by inhibiting PDEs, at least in part. 
 
In addition to resveratrol, other natural compounds that 
have been identified as STACs such as butein, fisetin 
and quercetin have also been identified to be PDE 
inhibitors [2,17].  This raises the question as to why so 
many compounds that are identified as STACs using the 
flurophore-tagged substrate turn out to be PDE 
inhibitors.  We can only speculate at this point, but one 
possibility is that by coincidence, the structure of the 
Sirt1 STAC-binding pocket has some similarity to the 
PDE catalytic pocket. 
 
Whether resveratrol can activate Sirt1 directly in 
addition to activating it indirectly (via PDE inhibition) 
remains to be seen. Even if resveratrol can activate Sirt1 
directly in vivo, it is not clear how much this effect will 
add to the well-known anti-inflammatory and anti-
diabetic effects produced by PDE4 inhibitors alone (e.g. 
the FDA-approved PDE4 inhibitor roflumilast) [18]. 
This question may take a while to answer.   
   
In conclusion, the discovery of the resveratrol-PDE link 
suggests that PDE4 inhibitors, possibly in combination 
with other PDE inhibitors, may be useful for mimicking 
CR and for treating aging-related diseases.  
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